Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common supplement slow lung scarring? new trial targets gene clue

NCT ID NCT04300920

Completed Disease control Sponsor: Fernando J Martinez Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the antioxidant N-acetylcysteine (NAC) can slow lung decline in people with idiopathic pulmonary fibrosis (IPF) who have a specific gene variant (TOLLIP TT). Over 200 participants took NAC or a placebo for 24 months. The goal was to see if NAC delays worsening lung function, hospital stays, or death. Results may help tailor IPF treatment based on genetics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
N-acetylcysteine (NAC) oral tablets
What this could lead to
If successful, this could show that NAC helps slow lung function decline in IPF patients with the TOLLIP TT genotype, offering a personalized treatment option.
What could go wrong
This is a completed phase 3 trial, but the benefit may be limited to a specific genetic subgroup. NAC is generally safe, but it may not work for all IPF patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • Lisa Lancaster

    Nashville, Tennessee, 37204, United States

  • Loyola University

    Maywood, Illinois, 60153, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Ohio State University

    Columbus, Ohio, 43221, United States

  • Piedmont Healthcare

    Austell, Georgia, 30106, United States

  • Stanford University

    Stanford, California, 94305, United States

  • Temple University

    Philadelphia, Pennsylvania, 19140, United States

  • Tulane University

    New Orleans, Louisiana, 70112, United States

  • University of Arizona

    Tucson, Arizona, 85724, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • University of Rochester

    Rochester, New York, 14642, United States

  • University of Southern California

    Los Angeles, California, 90033, United States

  • University of Texas Health San Antonio

    San Antonio, Texas, 78229, United States

  • University of Texas Southwestern

    Dallas, Texas, 75390, United States

  • University of Utah Health

    Salt Lake City, Utah, 84108, United States

  • University of Virginia

    Charlottesville, Virginia, 22908, United States

  • University of Washington

    Seattle, Washington, 98195, United States

  • Weill Cornell Medicine

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.